Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts

Efrat Bar-Ilan, Jonathan Bar, Avital Baniel, Dan Slodownik, Ofir Artzi, Liat Samuelov, Eli Sprecher, Jacob Mashiah*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Human papillomavirus (HPV) is ubiquitously distributed in the population worldwide and its most frequent clinical presentation is cutaneous warts. Despite various treatment options currently available, many patients experience persistent and refractory disease. We sought to evaluate the clinical effectiveness and safety profile of intralesional HPV 9-valent vaccine for the treatment of recalcitrant warts. A retrospective study was performed for all cases of cutaneous warts treated with intralesional 9-valent HPV vaccine between January 2017 and March 2021. Epidemiologic, clinical, and treatment data, including safety and effectiveness scores, were reviewed. Our cohort was composed of 20 patients: 13 adults and seven children. Twelve patients (60%) displayed a complete response whereas 8 patients (40%) showed a partial response. Older age was associated with a better response to treatment, while a history of laser therapy was associated with a worse prognosis. Adverse events were local, transient, and negligible. No systemic adverse effects were reported. Intralesional 9-valent HPV vaccine may be considered for the treatment of recalcitrant cutaneous warts. Controlled studies are required to confirm these results.

Original languageEnglish
Pages (from-to)1373-1380
Number of pages8
JournalJournal of Dermatology
Issue number11
StatePublished - Nov 2023


  • human papillomavirus
  • local therapy
  • pediatric dermatology
  • vaccines
  • verruca


Dive into the research topics of 'Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts'. Together they form a unique fingerprint.

Cite this